Hologic (NASDAQ:HOLX) Downgraded by Leerink Partnrs to Hold

Leerink Partnrs lowered shares of Hologic (NASDAQ:HOLX) from a strong-buy rating to a hold rating in a report published on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Hologic’s Q3 2025 earnings at $1.10 EPS, FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.

Several other analysts also recently weighed in on HOLX. Jefferies Financial Group began coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Stephens reaffirmed an “overweight” rating and set a $84.00 target price on shares of Hologic in a research report on Thursday. Mizuho dropped their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday. Finally, Raymond James reiterated an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Stock Performance

NASDAQ:HOLX opened at $65.45 on Thursday. The firm has a market capitalization of $14.77 billion, a PE ratio of 19.65, a PEG ratio of 2.35 and a beta of 0.98. The stock’s fifty day moving average is $72.63 and its 200 day moving average is $77.86. Hologic has a fifty-two week low of $64.87 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. On average, sell-side analysts anticipate that Hologic will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.88% of the company’s stock.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Nordea Investment Management AB raised its holdings in Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Hologic during the 4th quarter valued at approximately $27,007,000. Swedbank AB grew its position in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.